Sanofi
No SEC Form 4 filings for $SNY in the last 30 days.
See all $SNY insider activity →Morningstar says 55% of US-listed stocks it covers beat FactSet earnings by at least 5% as of Aug. 11. It screened for six undervalued “earnings crushers” with 10%+ EPS beats and 5%+ revenue beats, including Albemarle, Atlassian, Baxter International, CarMax, Ionis Pharmaceuticals, and Sanofi, citing EPS, revenue, Morningstar ratings, and discounts to fair value.
A retrospective Medicare study of steroid-refractory polymyalgia rheumatica (415 matched pairs) found IL-6 receptor inhibitors tocilizumab or sarilumab plus glucocorticoids led more patients to discontinue or minimize glucocorticoids by year 1 versus csIM therapies (HR 1.28, P=.031/.025) and versus methotrexate (P=.11/.022). Safety was similar except higher hospitalized infections in year 1.
Sanofi will reorganize its Executive Committee effective Sept. 1, expanding the finance function to cover enterprise business services, global partnering, business development, and M&A, with François Roger continuing as EVP of Finance. The company also names Belén Garijo as incoming CEO and appoints Jamie Haney as General Counsel. Separately, Sanofi agreed to buy Vigil Neuroscience for about $470M.
Over the past 7 days, alphai's AI scored 9 news stories mentioning SNY (Sanofi). Coverage has skewed bullish: 3 bullish, 6 neutral, and 0 bearish.
Recent SNY coverage spans sector analysis, financial news and corporate actions.
Insufficient detail in the excerpt to assess the specific catalyst beyond the fact it met the screen criteria.
Indirectly supportive for Sanofi’s IL-6Ri positioning, but not a new approval, label change, or trial result.
Management and governance changes plus expanded finance scope can shift deal and partnering execution pace, but no direct financial guidance is provided.
Pipeline pruning reduces future R&D cash burn but raises uncertainty about a dermatology successor to Dupixent.
Launch-driven sales growth is accompanying higher expenses, implying investment is translating into topline momentum.
alphai scores every news story that mentions SNY with an AI model for sentiment and relevance, and aggregates insider trades from Sanofi's SEC EDGAR Form 4 filings. Figures refresh continuously.
Morningstar says 55% of US-listed stocks it covers beat FactSet earnings by at least 5% as of Aug. 11. It screened for six undervalued “earnings crushers” with 10%+ EPS beats and 5%+ revenue beats, including Albemarle, Atlassian, Baxter International, CarMax, Ionis Pharmaceuticals, and Sanofi, citing EPS, revenue, Morningstar ratings, and discounts to fair value.
7 min readA retrospective Medicare study of steroid-refractory polymyalgia rheumatica (415 matched pairs) found IL-6 receptor inhibitors tocilizumab or sarilumab plus glucocorticoids led more patients to discontinue or minimize glucocorticoids by year 1 versus csIM therapies (HR 1.28, P=.031/.025) and versus methotrexate (P=.11/.022). Safety was similar except higher hospitalized infections in year 1.
6 min readSanofi will reorganize its Executive Committee effective Sept. 1, expanding the finance function to cover enterprise business services, global partnering, business development, and M&A, with François Roger continuing as EVP of Finance. The company also names Belén Garijo as incoming CEO and appoints Jamie Haney as General Counsel. Separately, Sanofi agreed to buy Vigil Neuroscience for about $470M.
4 min readSanofi (NASDAQ:SNY) shares fell in Europe after the company decided to stop developing amlitelimab for moderate-to-severe atopic dermatitis, citing efficacy and safety data that did not support global regulatory filings. Morgan Stanley trimmed its price target to $49 from $52 (Equal Weight). Investors are watching Sanofi’s July 30 Q2 results and Dupixent growth.
5 min readA roundup of Q2 earnings trends for major pharma and biotech firms highlights GLP-1 marketing spend, biosimilar and generic competition, and China-related risks. Eli Lilly raised Q2 marketing expenses 25% to $3.43B and lifted year-end revenue guidance to $85B-$87B. Novo Nordisk reported 5M Wegovy pill prescriptions in 30 weeks. Pfizer cut promotional costs and plans $2.5B savings (2027-29).
7 min readAnalyst estimates cited by FactSet show Sanofi’s average 12-month price target was cut to $50 from $50.6. The new range is $45 to $57 per share. Based on the Aug. 7 closing price, the target implies about 15% upside. The consensus rating remains “Buy” with 3 Buys, 4 Holds, and 0 Sells.
1 min readA JAMA Network Open analysis of two US surveys (174 pregnant women, 1,765 parents) found 58.2% of pregnant women and 48.3% of parents preferred Pfizer’s maternal RSV vaccine Abrysvo over infant antibody injections (AstraZeneca/Sanofi nirsevimab, Merck clesrovimab). Hesitancy cited limited RSV knowledge and safety concerns. Provider recommendations could increase acceptance among unsure groups.
5 min readGlobal drugmakers plan major U.S. manufacturing and R&D expansions, citing supply-chain resilience and tariff risk. The article says companies including Pfizer, GSK, Eli Lilly, J&J, Roche, AstraZeneca, Novartis, Sanofi, Biogen, Merck, Amgen, AbbVie, Gilead, Bristol Myers Squibb, Cipla, and CSL have pledged about US$500 billion. Examples include Pfizer’s US$70B, Lilly’s US$27B-plus, and Merck’s US$70B-plus.
7 min readReuters factbox says global drugmakers are pledging about $500 billion in U.S. investments to expand manufacturing and R&D and reduce supply-chain and tariff risks. Examples include Pfizer’s $70 billion R&D and manufacturing deal, Eli Lilly’s plans totaling $55 billion, and AstraZeneca’s $50 billion by 2030, plus Roche, Sanofi, Merck, Amgen and others.
7 min readBiotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.
7 min read
